T. Neff

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

H. Goldschmidt, M. Boccadoro, M. Jenner, 2021, Advances in Therapy.

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

M. Beksac, H. Goldschmidt, C. Hofmeister, 2020, Leukemia.

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

H. Goldschmidt, C. Hofmeister, P. Moreau, 2018, Blood.

Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.

H. Goldschmidt, M. Dimopoulos, S. Rajkumar, 2018 .

An Unusual Case of Congenital Primitive Neuroectodermal Tumor With Ocular Metastasis

D. Vanderveen, S. Vargas, L. Frazier, 2012, Journal of pediatric hematology/oncology.

Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

H. Goldschmidt, C. Hofmeister, P. Voorhees, 2017 .

Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

James D. Clarke, A. El-Khoueiry, B. Tran, 2023, British Journal of Cancer.